[
  {
    "ts": null,
    "headline": "BIOGEN : TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS JULY 31, 2025",
    "summary": "Cambridge, Mass.- Biogen Inc. today announced it will report second quarter 2025 financial results Thursday, July 31, 2025, before the financial markets open. Following the...",
    "url": "https://finnhub.io/api/news?id=7aa0460938b178cfe7ff3a271ec592aa31557e2ed62c6a983953884d2ed0e41b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751299987,
      "headline": "BIOGEN : TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS JULY 31, 2025",
      "id": 135674515,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Cambridge, Mass.- Biogen Inc. today announced it will report second quarter 2025 financial results Thursday, July 31, 2025, before the financial markets open. Following the...",
      "url": "https://finnhub.io/api/news?id=7aa0460938b178cfe7ff3a271ec592aa31557e2ed62c6a983953884d2ed0e41b"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy",
    "summary": "Biogen Inc. announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to...",
    "url": "https://finnhub.io/api/news?id=45e7283659a02c97a0616cca407ed56f0cbdc445e71df4a0202448c9c4b171c7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751296887,
      "headline": "Biogen Inc. Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy",
      "id": 135672479,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Biogen Inc. announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to...",
      "url": "https://finnhub.io/api/news?id=45e7283659a02c97a0616cca407ed56f0cbdc445e71df4a0202448c9c4b171c7"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc.(NasdaqGS: BIIB) added to Russell 1000 Value-Defensive Index",
    "summary": "Biogen Inc. added to Russell 1000 Value-Defensive Index...",
    "url": "https://finnhub.io/api/news?id=bac0270fc1de8e13b851d6489d29ff73601c38b92c3a806b4ae7dbd818ae1284",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751292520,
      "headline": "Biogen Inc.(NasdaqGS: BIIB) added to Russell 1000 Value-Defensive Index",
      "id": 135666630,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Biogen Inc. added to Russell 1000 Value-Defensive Index...",
      "url": "https://finnhub.io/api/news?id=bac0270fc1de8e13b851d6489d29ff73601c38b92c3a806b4ae7dbd818ae1284"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to buy Capstan for up to $2.1 billion in immunology push",
    "summary": "(Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments for autoimmune diseases.  The U.S. drugmaker has spent over $20 billion on acquisitions since 2023 as its flagship rheumatoid arthritis drug, Humira, lost patent protection.  Capstan develops CAR-T therapies, which use a patient's own immune cells, specifically T-cells, to fight diseases.",
    "url": "https://finnhub.io/api/news?id=1ae7614f475c00531f3dbe2acbf715de5078e4f06d6d3394596db612a35b334f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751287323,
      "headline": "AbbVie to buy Capstan for up to $2.1 billion in immunology push",
      "id": 135666209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "(Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments for autoimmune diseases.  The U.S. drugmaker has spent over $20 billion on acquisitions since 2023 as its flagship rheumatoid arthritis drug, Humira, lost patent protection.  Capstan develops CAR-T therapies, which use a patient's own immune cells, specifically T-cells, to fight diseases.",
      "url": "https://finnhub.io/api/news?id=1ae7614f475c00531f3dbe2acbf715de5078e4f06d6d3394596db612a35b334f"
    }
  },
  {
    "ts": null,
    "headline": "RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market",
    "summary": "Investing.com -- RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pave the way for Biogen’s Leqembi to follow with significant commercial success.",
    "url": "https://finnhub.io/api/news?id=aa3fd58b3af4e34e4d99f93669cc36a6924b778285e9f813fadfcf28a283837d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751285932,
      "headline": "RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market",
      "id": 135671332,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Investing.com -- RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pave the way for Biogen’s Leqembi to follow with significant commercial success.",
      "url": "https://finnhub.io/api/news?id=aa3fd58b3af4e34e4d99f93669cc36a6924b778285e9f813fadfcf28a283837d"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy",
    "summary": "Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved for PMN, a rare immune-mediated disease affecting the kidneys with an estimated prevalence of ~36k patients in the U.S.1Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-medi",
    "url": "https://finnhub.io/api/news?id=616e996e9017aa0853683e18d7569f51801d799b96336df19f98f4d51d833135",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751283000,
      "headline": "Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy",
      "id": 135672316,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved for PMN, a rare immune-mediated disease affecting the kidneys with an estimated prevalence of ~36k patients in the U.S.1Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-medi",
      "url": "https://finnhub.io/api/news?id=616e996e9017aa0853683e18d7569f51801d799b96336df19f98f4d51d833135"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc.(NasdaqGS: BIIB) added to Russell 1000 Defensive Index",
    "summary": "Biogen Inc. added to Russell 1000 Defensive Index...",
    "url": "https://finnhub.io/api/news?id=b379302d6de81f621e3c126694bf877871f310569635559ea6ab59e1ae6c66b4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751280344,
      "headline": "Biogen Inc.(NasdaqGS: BIIB) added to Russell 1000 Defensive Index",
      "id": 135653490,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Biogen Inc. added to Russell 1000 Defensive Index...",
      "url": "https://finnhub.io/api/news?id=b379302d6de81f621e3c126694bf877871f310569635559ea6ab59e1ae6c66b4"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Launches Phase 3 Study of Felzartamab in Rare Kidney Disease PMN",
    "summary": "Biogen Launches Phase 3 Study of Felzartamab in Rare Kidney Disease PMN",
    "url": "https://finnhub.io/api/news?id=613797cf2a3098fea66d75d1e072cfce3882c65d38d69219415f36d98b7aee71",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751269980,
      "headline": "Biogen Launches Phase 3 Study of Felzartamab in Rare Kidney Disease PMN",
      "id": 135989073,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Launches Phase 3 Study of Felzartamab in Rare Kidney Disease PMN",
      "url": "https://finnhub.io/api/news?id=613797cf2a3098fea66d75d1e072cfce3882c65d38d69219415f36d98b7aee71"
    }
  }
]